Department of Analytical Chemistry and Pharmaceutical Technology, Center for Pharmaceutical Research (CePhaR), Vrije Universiteit Brussel-VUB, Laarbeeklaan 103, Brussels 1090, Belgium.
Anal Bioanal Chem. 2010 Sep;398(1):239-64. doi: 10.1007/s00216-010-3857-7. Epub 2010 Jun 13.
Use of microfluidic devices in the life sciences and medicine has created the possibility of performing investigations at the molecular level. Moreover, microfluidic devices are also part of the technological framework that has enabled a new type of scientific information to be revealed, i.e. that based on intensive screening of complete sets of gene and protein sequences. A deeper bioanalytical perspective may provide quantitative and qualitative tools, enabling study of various diseases and, eventually, may offer support for the development of accurate and reliable methods for clinical assessment. This would open the way to molecule-based diagnostics, i.e. establish accurate diagnosis and disease prognosis based on identification and/or quantification of biomacromolecules, for example proteins or nucleic acids. Finally, the development of disposable and portable devices for molecule-based diagnosis would provide the perfect translation of the science behind life-science research into practical applications dedicated to patients and health practitioners. This review provides an analytical perspective of the impact of microfluidics on the detection and characterization of bio-macromolecules involved in pathological processes. The main features of molecule-based diagnostics and the specific requirements for the diagnostic devices are discussed. Further, the techniques currently used for testing bio-macromolecules for potential diagnostic purposes are identified, emphasizing the newest developments. Subsequently, the challenges of this type of application and the status of commercially available devices are highlighted, and future trends are noted.
微流控芯片在生命科学和医学中的应用开创了在分子水平进行研究的可能性。此外,微流控芯片也是揭示新型科学信息的技术框架的一部分,即基于对整套基因和蛋白质序列的密集筛选。更深入的生物分析视角可以提供定量和定性的工具,从而研究各种疾病,并最终可能为开发准确可靠的临床评估方法提供支持。这将为基于分子的诊断开辟道路,即基于生物大分子(例如蛋白质或核酸)的识别和/或定量来进行准确的诊断和疾病预后。最后,用于基于分子的诊断的一次性和便携式设备的开发将为生命科学研究背后的科学转化为专注于患者和医疗从业者的实际应用提供完美的途径。本综述从分析的角度探讨了微流控技术对涉及病理过程的生物大分子的检测和表征的影响。讨论了基于分子的诊断的主要特点和诊断设备的特定要求。此外,还确定了目前用于测试潜在诊断用途的生物大分子的技术,强调了最新的发展。随后,突出了此类应用的挑战和市售设备的现状,并指出了未来的趋势。